Everything below concerns RP-HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-12. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Studies on the effect of drugs on trypanothione metabolism resulted in the discovery that fexinidazole is a potential oral treatment for visceral leishmaniasis. In 2006 Fairlamb and Mike Ferguson became co-directors of the Drug Discovery Unit at the University of Dundee. The new centre, opened in 2005, has facilities for high-throughput screening and medicinal chemistry. These will take the drug discovery/development process further than any other UK university, to a stage where pharmaceutical companies will have sufficient data to move into the production stage.
He visited Calabria Citeriore, Sibari, Corigliano, Rossano, Cirò and Strongoli. Charles met the Dean of Catanzaro on the borders of Calabria Ulterior, stopped in Crotone and in Cutro, and stayed four days in Catanzaro, before visiting Monteleone and then Palmi. From there, Charles embarked for Messina. From the earliest years the reforming action of King Charles, aided by Tuscan minister Bernardo Tanucci, was aimed at strengthening central power at the expense of baronial and clerical power. He also worked to alleviate the social and economic conditions of the poor, with at best modest results, due to the resistance of the local ruling classes, fighting to protect their privileges and particularistic interests. One particularly reformed field was economic and fiscal: in 1739 the Supreme Magistrate of Commerce was created, consisting of magistrates, technicians, merchants and bankers, with absolute jurisdiction over trade. In 1741 a Concordat was made with the Holy See, allowing ecclesiastical properties in the Kingdom of Naples to be taxed, while in the same period the Catasto onciario was commissioned, so called because it was measured in ounces (nominal currency equal to 6 ducats or 60 carlins), which was supposed to reorder the tax burden by lowering taxes on the poorest. However, nobles and clergymen enjoyed exemptions that protected their interests. In 1759, however, King Charles, as a result of diplomatic agreements and complicated family events, had to abdicate the throne of Naples to secure the crown of Spain after the death of his half-brother Ferdinand VI.
== Plot == A doctor informs fourth grader Eric Cartman and his mother Liane that his obesity is a threat to his health. When Liane says that proper diet and exercise has not worked for him, the doctor recommends a diabetes drug called semaglutide, which has been shown to help people lose weight. This prompts Cartman to fantasize about being able to viciously insult people with impunity without fear of being mocked for his weight, and even going all the way to Pakistan to continue this. However, insurance companies only cover the drug for diabetes, and are too expensive for Liane. The doctor prescribes that Cartman listen to the music of Lizzo, who frequently encourages body positivity. This leaves Cartman despondent, so his friends, Butters Stotch and Kyle Broflovski, accompany him to an insurance company office. However, when they request to make a claim with a dejected-looking claims officer, they are sent on a labyrinthine journey through the bureaucracy of the American health care system. They ultimately decide to make it themselves after learning the raw semaglutide powder can be purchased cheaply from a factory in India and mixed with biostatic water purchased locally. Their other friends, Stan Marsh and Kenny McCormick, join them in this scheme. Meanwhile, Randy Marsh observes many local mothers wearing crop-tops after attaining toned midriffs after losing weight with semaglutide, a recurring visual gag in the episode.
== Figurative use == The term poison is also used in a figurative sense. The slang sense of alcoholic drink is first attested 1805, American English (e.g., a bartender might ask a customer "what's your poison?" or "Pick your poison"). Figurative use of the term dates from the late 15th century. Figuratively referring to persons as poison dates from 1910. The figurative term poison pen letter became well known in 1913 by a notorious criminal case in Pennsylvania, U.S.; the phrase dates to 1898. Despite the plants of the Toxicodendron family having the names poison ivy and poison oak, the oil urushiol they produce is not a true poison and is actually an allergen, which 15% of people are resistant to.
Sources: en.wikipedia.org
When properly delivered, it has a low rate of mostly minor adverse effects. When accidents and infections do occur, they are associated with neglect on the part of the practitioner, particularly in the application of sterile techniques. A review conducted in 2013 stated that reports of infection transmission increased significantly in the preceding decade. The most frequently reported adverse events were pneumothorax and infections. Since serious adverse events continue to be reported, it is recommended that acupuncturists be trained sufficiently to reduce the risk. Scientific investigation has not found any histological or physiological evidence for traditional Chinese concepts such as qi, meridians, and acupuncture points, and many modern practitioners no longer support the existence of qi or meridians, which was a major part of early belief systems. Acupuncture is believed to have originated around 100 BC in China, around the time The Inner Classic of Huang Di (Huangdi Neijing) was published, though some experts suggest it could have been practiced earlier. Over time, conflicting claims and belief systems emerged about the effect of lunar, celestial and earthly cycles, yin and yang energies, and a body's "rhythm" on the effectiveness of treatment. Acupuncture fluctuated in popularity in China due to changes in the country's political leadership and the preferential use of rationalism or scientific evidence-based medicine. Acupuncture spread first to Korea in the 6th century AD, then to Japan through medical missionaries, and then to Europe, beginning with France.
The consequence of this double strand instability will be a mismatch of the two DNA strands in the region of polymorphism when DNA is heated to the DNA melting temperature. This mismatch will therefore decrease the interaction with the column and will result in a reduced retention time compared to the homoduplexes in the chromatographic separation process. To observe the phenomenon of separation, the DHPLC method uses a column of a non-grafted porous stationary phase composed of polystyrene-divinylbenzene alkyl. The stationary phase is electrically neutral and hydrophobic. The DNA, however, is negatively charged at its phosphate groups and therefore can adsorb itself on the column. In order to make the adsorption possible, triethylammonium acetate (TEAA) is used. The positively charged ammonium ion of these molecules interacts with the DNA, and the alkyl chain with the hydrophobic surface of the solid phase. Therefore, when heteroduplexes are partially denaturated by heating, the negative charges undergo partial relocation and the interaction force between DNA heteroduplexes and column decreases in comparison to the strength of interaction of the homoduplexes. These will therefore be eluted less rapidly by the mobile phase (consisting of acetonitrile).
Copper is the traditional material for the boiling vessel for two main reasons: firstly because copper transfers heat quickly and evenly; secondly because the bubbles produced during boiling, which could act as an insulator against the heat, do not cling to the surface of copper, so the wort is heated in a consistent manner. The simplest boil kettles are direct-fired, with a burner underneath. These can produce a vigorous and favourable boil, but are also apt to scorch the wort where the flame touches the kettle, causing caramelisation and making cleanup difficult. Most breweries use a steam-fired kettle, which uses steam jackets in the kettle to boil the wort. Breweries usually have a boiling unit either inside or outside of the kettle, usually a tall, thin cylinder with vertical tubes, called a calandria, through which wort is pumped.
Sources: en.wikipedia.org
=== Circumcision === Lidocaine/prilocaine eutectic mixture has been used during circumcision in newborn boys and has been considered efficacious and safe to lessen pain from circumcision. The European Medicines Agency concludes in its latest (2014) statement on Emla: "Safety and efficacy for the use of EMLA on genital skin and genital mucosa have not been established in children younger than 12 years. Available paediatric data do not demonstrate adequate efficacy for circumcision." The Patient Information Leaflet of EMLA in the UK states: "EMLA Cream should not be applied to the genital skin (e.g. penis) and genital mucosa (e.g. in the vagina) of children (below 12 years of age) owing to insufficient data on absorption of active substances."
An official independence referendum happens later in December August 25: Belarus declares independence from the Soviet Union. August 27: Moldova declares independence from the Soviet Union. August 31: Uzbekistan and Kyrgyzstan declare independence from the Soviet Union. September: 1991 Zaire unrest occurred. September 7: Macedonia holds an independence referendum with a majority voting in favor of independence. September 9: Tajikistan declares independence from the Soviet Union. September 21: Armenia holds an independence referendum with a majority voting for independence from the Soviet Union despite declaring independence in August 1990. October 26: Turkmenistan holds an independence referendum with a majority voting for independence from the Soviet Union. October 27: Turkmenistan declares its independence from the Soviet Union. October 31: The Djiboutian Civil War begins. November 1: Chechnya declares sovereignty. November 12: The Indonesian Army massacred at least 250 East Timorese pro-independence protesters during the Indonesian occupation of East Timor. December 1: Ukraine holds an independence referendum with a majority voting in favor of independence. December 16: Kazakhstan declares its full independence from the Soviet Union. December 22: The Georgian Civil War begins. December 25: Mikhail Gorbachev resigns as President of the USSR. The flag of the Soviet Union is lowered for the last time over the Kremlin and is later replaced by the Russian flag. Also that day U.S. President George H. W.
At an ultrastructural level the weakening of the corneal tissue is associated with a disruption of the regular arrangement of the collagen layers and collagen fibril orientation. While keratoconus is considered a noninflammatory disorder, one study shows wearing rigid contact lenses by people leads to overexpression of proinflammatory cytokines, such as IL-6, TNF-alpha, ICAM-1, and VCAM-1 in the tear fluid. A genetic predisposition to keratoconus has been observed, with the disease running in certain families, and incidences reported of concordance in identical twins. The frequency of occurrence in close family members is not clearly defined, though it is known to be considerably higher than that in the general population, and studies have obtained estimates ranging between 6% and 19%. Two studies involving isolated, largely homogenetic communities have contrarily mapped putative gene locations to chromosomes 16q and 20q. Most genetic studies agree on an autosomal dominant model of inheritance. A rare, autosomal dominant form of severe keratoconus with anterior polar cataract is caused by a mutation in the seed region of mir-184, a microRNA that is highly expressed in the cornea and anterior lens. Keratoconus is diagnosed more often in people with Down's syndrome, though the reasons for this link have not yet been determined. Researches also have shed light on the role of hormones in the pathophysiology of keratoconus.
Polyurethanes contain multiple carbamate groups as part of their structure. The "urethane" in the name "polyurethane" refers to these carbamate groups; the term "urethane links" describe how carbamates polymerize. In contrast, the substance commonly called "urethane", ethyl carbamate, is neither a component of polyurethanes, nor is it used in their manufacture. Urethanes are usually formed by reaction of an alcohol with an isocyanate. Commonly, urethanes made by a non-isocyanate route are called carbamates. Polyurethane polymers have a wide range of properties and are commercially available as foams, elastomers, and solids. Typically, polyurethane polymers are made by combining diisocyanates, e.g. toluene diisocyanate, and diols, where the carbamate groups are formed by reaction of the alcohols with the isocyanates:
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.